IPO Search (symbol or name)
Home
Our Passion for IPOs
Calendars
Upcoming IPOs
News & Views
Breaking News
Featured IPO
Pricings
Today's
Recent
Rankings
Largest Global IPOs
Largest US IPOs
Largest US IPOs YTD
Largest US Internet IPOs
Top First Day Returns
Underwriters
Directory
Interactive
IPO Poll
Register
US IPO Stats
US Market
IPO Volume
IPO Pricings
IPO Returns
IPO Filings
IPO Withdrawals
IPO Average Age
IPO Industry Breakdown
Offer Price Discounts
Underwriter Rankings
Global IPO Stats
Global Market
IPO Volume
IPO Pricings
IPOs by Region
IPO Race
IPO Industry Breakdown
Reviews
1Q 2012 Global IPO Review
2011 Global IPO Review
Internet IPOs
Chinese IPOs
2011 IPO Pipeline Review
Press
Press Room
Press Contact Form
Free iPhone App
Free Android App
IPO News Feed
Follow ipoTweet
Endocyte (ECYT)
Latest Trade:
$6.55
$6.55
IPO News
Endocyte quiet period ends March 15
3/10/11
With much delay, cancer drug developer Endocyte opens for trading
2/4/11
Endocyte modifies IPO terms for the second time; drops estimated offer price to $6
2/4/11
Ovarian cancer drug developer Endocyte amends IPO terms
2/3/11
Endocyte discloses terms for $75 million IPO
1/12/11
Endocyte submits filing for $86 million IPO
8/17/10
Interested in IPO Investing?
IPO Performance
First Day Return
7.7300
28.8%
Aftermarket Return
7.7300
-15.3%
Return from IPO
6.0000
9.2%
IPO Profile
IPO Date
02/03/11
Offer Price
$6.00
Offer Shares
12.5 mm
Lead Manager(s)
RBC Capital Markets
Leerink Swann
Co Manager(s)
Wedbush PacGrow
All Underwriters
Business
Business
Is developing EC145 (entering Phase III) for the treatment of ovarian cancer.
Industry
Health-Drugs
Employees
54
Founded
1995
ECYT Daily
Chart
Corporate Data
Company Address
3000 Kent Avenue, Suite A1-100
West Lafayette, IN
Phone Number
(765) 463-7175
Web Address
www.endocyte.com